Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3687586rdf:typepubmed:Citationlld:pubmed
pubmed-article:3687586lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:3687586pubmed:issue3-4lld:pubmed
pubmed-article:3687586pubmed:dateCreated1988-1-19lld:pubmed
pubmed-article:3687586pubmed:abstractTextIndomethacin was administered subcutaneously to rats, 4 mg/kg/day for 4 consecutive days in order to produce erosions of the small intestine which were scored at necropsy on day 5. Orally administered phenidone (up to 250 mg/kg/day), a mixed cycloocygenase-lipoxygenase inhibitor, failed to produce intestinal erosions, but tended to exacerbate indomethacin-induced erosions. A 5-LO inhibitor, diphenyldisulfide, provided significant protection at 10-100 mg/kg when given orally to indomethacin-treated rats. Sulfasalazine, auranofin and cyproheptadine, but not cimetidine, also protected, suggesting a role for mast cell activation and leukotriene generation in indomethacin-induced ulcerogenesis.lld:pubmed
pubmed-article:3687586pubmed:languageenglld:pubmed
pubmed-article:3687586pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3687586pubmed:citationSubsetIMlld:pubmed
pubmed-article:3687586pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3687586pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3687586pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3687586pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3687586pubmed:statusMEDLINElld:pubmed
pubmed-article:3687586pubmed:monthAuglld:pubmed
pubmed-article:3687586pubmed:issn0065-4299lld:pubmed
pubmed-article:3687586pubmed:authorpubmed-author:YoungJ MJMlld:pubmed
pubmed-article:3687586pubmed:authorpubmed-author:TomolonisA...lld:pubmed
pubmed-article:3687586pubmed:issnTypePrintlld:pubmed
pubmed-article:3687586pubmed:volume21lld:pubmed
pubmed-article:3687586pubmed:ownerNLMlld:pubmed
pubmed-article:3687586pubmed:authorsCompleteYlld:pubmed
pubmed-article:3687586pubmed:pagination314-5lld:pubmed
pubmed-article:3687586pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:3687586pubmed:meshHeadingpubmed-meshheading:3687586-...lld:pubmed
pubmed-article:3687586pubmed:meshHeadingpubmed-meshheading:3687586-...lld:pubmed
pubmed-article:3687586pubmed:meshHeadingpubmed-meshheading:3687586-...lld:pubmed
pubmed-article:3687586pubmed:meshHeadingpubmed-meshheading:3687586-...lld:pubmed
pubmed-article:3687586pubmed:meshHeadingpubmed-meshheading:3687586-...lld:pubmed
pubmed-article:3687586pubmed:meshHeadingpubmed-meshheading:3687586-...lld:pubmed
pubmed-article:3687586pubmed:meshHeadingpubmed-meshheading:3687586-...lld:pubmed
pubmed-article:3687586pubmed:meshHeadingpubmed-meshheading:3687586-...lld:pubmed
pubmed-article:3687586pubmed:year1987lld:pubmed
pubmed-article:3687586pubmed:articleTitleDiphenyldisulfide inhibits indomethacin-induced ulcerogenesis in rats.lld:pubmed
pubmed-article:3687586pubmed:affiliationInstitute of Biological Sciences, Syntex Research, Palo Alto, CA 94304.lld:pubmed
pubmed-article:3687586pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3687586lld:pubmed